Association studies of HFE C282Y and H63D variants with oral cancer risk and iron homeostasis among whites and blacks

Cancers

Volumn 7, Issue 4, 2015, Pages 2386-2396

  Jones, Nathan R ^a   Ashmore, Joseph H ^b   Lee, Sang Y ^a   Richie, John P ^a   Lazarus, Philip ^a,b   Muscat, Joshua E ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Black; Genotyping; HFE; Iron homeostasis; Oral cancer; SNP; White

Indexed keywords

FERRITIN; IRON;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; ETHNICITY; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEMOCHROMATOSIS; HFE GENE; HOMEOSTASIS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IRON BLOOD LEVEL; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MOUTH SQUAMOUS CELL CARCINOMA; ONCOGENE; PLESIOMORPHY; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SPECTROPHOTOMETRY; STRUCTURED QUESTIONNAIRE;

EID: 84949775253     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7040898     Document Type: Article

References (61)

1. Feder, J.N.; Gnirke, A.; Thomas, W.; Tsuchihashi, Z.; Ruddy, D.A.; Basava, A.; Dormishian, F.; Domingo, R., Jr.; Ellis, M.C.; Fullan, A. et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 1996, 13, 399–408. [CrossRef] [PubMed]
2. Feder, J.N.; Tsuchihashi, Z.; Irrinki, A.; Lee, V.K.; Lebron, J.A.; Watson, N.; Tsuchihashi, Z.; Sigal, E.; Bjrorkman, P.J.; Schatzman, R.C. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J. Biol. Chem. 1997, 272, 14025–14028. [CrossRef][PubMed]
3. Waheed, A.; Parkkila, S.; Zhou, X.Y.; Tomatsu, S.; Tsuchihashi, Z.; Feder, J.N.; Schatzman, R.C.; Britton, R.S.; Bacon, B.R.; Sly, W.S. Hereditary hemochromatosis: Effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc. Natl. Acad. Sci. USA 1997, 94, 12384–12389. [CrossRef] [PubMed]
4. Cauza, E.; Peck-Radosavljevic, M.; Ulrich-Pur, H.; Datz, C.; Gschwantier, M.; Schoniger-Hekele, F.; Polli, C.; Rasoul-Rockenschaub, S.; Muller, C.; Wrba, F. et al. Mutations of the HFE gene in patients with hepatocellular carcinoma. Am. J. Gastroenterol. 2003, 98, 442–447. [CrossRef] [PubMed]
5. Jin, F.; Qu, L.S.; Shen, X.Z. Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: A meta-analysis. J. Exp. Clin. Cancer Res. 2010,29, 18. [CrossRef] [PubMed]
6. Jin, F.; Xiong, W.J.; Jing, J.C.; Feng, Z.; Qu, L.S.; Shen, X.Z. Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: A systematic review. J. Cancer Res. Clin. Oncol. 2011, 137, 1095–1104. [CrossRef] [PubMed]
7. Feder, J.N.; Penny, D.M.; Irrinki, A.; Lee, V.K.; Lebron, J.A.; Watson, N.; Tsuchihashi, Z.; Sigal, E.; Bjrorkman, P.J.; Schatzman, R.C. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc. Natl. Acad. Sci. USA 1998, 95, 1472–1477. [CrossRef][PubMed]
8. Brandhagen, D.J.; Fairbanks, V.F.; Baldus, W.P.; Smith, C.I.; Kruckeberg, K.E.; chaid, D.J.; Thibodeau, S.N. Prevalence and clinical significance of HFE gene mutations in patients with iron overload. Am. J. Gastroenterol. 2000, 95, 2910–2914. [CrossRef] [PubMed]
9. Cassanelli, S.; Pignatti, E.; Montosi, G.; Garuti, C.; Mariano, M.; Campioli, D.; Carbonieri, A.; Baldini, E.; Pietrangelo, A. Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE) gene mutations in the healthy adult population in Italy. J. Hepatol. 2001, 34, 523–528. [CrossRef]
10. Fairbanks, V.F.; Brandhagen, D.J.; Thibodeau, S.N.; Snow, K.; Wollan, P.C. H63D is an haemochromatosis associated allele. Gut 1998, 43, 441–442. [CrossRef] [PubMed]
11. Steinberg, K.K.; Cogswell, M.E.; Chang, J.C.; Caudill, S.P.; McQuillan, G.M.; Bowman, B.A.; Grummer-Strawn, L.M.; Sampson, E.J.; Khoury, M.J.; Gallagher, M.L. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001, 285, 2216–2222.[CrossRef] [PubMed]
12. Kew, M.C. Hepatic iron overload and hepatocellular carcinoma. Cancer Lett. 2009, 286, 38–43. [CrossRef][PubMed]
13. MacDonald, G.A.; Bridle, K.R.; Ward, P.J.; Walker, N.I.; Houglum, K.; George, K.; Smith, J.L.; Crawford, D.H.; Ramm, G.A. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. J. Gastroenterol. Hepatol. 2001, 16, 599–606. [CrossRef] [PubMed]
14. Puliyel, M.; Mainous, A.G.; Berdoukas, V.; Coates, T.D. Iron toxicity and its possible association with treatment of Cancer: Lessons from hemoglobinopathies and rare, transfusion-dependent anemias. Free Radic. Biol. Med. 2015, 79, 343–351. [CrossRef] [PubMed]
15. Zhang, C.; Zhang, F. Iron homeostasis and tumorigenesis: Molecular mechanisms and therapeutic opportunities. Protein Cell 2015, 6, 88–100. [CrossRef] [PubMed]
16. Abraham, B.K.; Justenhoven, C.; Pesch, B.; Harth, V.; Weirich, G.; Baisch, C.; Rabstein, S.; Ko, Y.D.; Bruning, T.; Fischer, H.P. et al. Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 1102–1107. [CrossRef] [PubMed]
17. Altes, A.; Gimferrer, E.; Capella, G.; Barcelo, M.J.; Baiget, M. Colorectal cancer and HFE gene mutations. Haematologica 1999, 84, 479–480. [PubMed]
18. Barton, J.C.; Bertoli, L.F.; Acton, R.T. HFE C282Y and H63D in adults with malignancies in a community medical oncology practice. BMC Cancer 2004, 4, 6. [CrossRef] [PubMed]
19. Cardoso, C.S.; Araujo, H.C.; Cruz, E.; Afonso, A.; Mascarenhas, C.; Moutinho, J.; Lopes, C.; Medeiros, R. Haemochromatosis gene (HFE) mutations in viral-associated neoplasia: Linkage to cervical cancer. Biochem. Biophys. Res. Commun. 2006, 341, 232–238.[CrossRef] [PubMed]
20. Dorak, M.T.; Burnett, A.K.; Worwood, M.; Sproul, A.M.; Gibson, B.E. The C282Y mutation of HFE is another male-specific risk factor for childhood acute lymphoblastic leukemia. Blood 1999, 94, 3957–3958. [PubMed]
21. Gimferrer, E.; Nomdedeu, J.; Gich, I.; Barcelo, M.J.; Baiget, M. Prevalence of hemochromatosis related HFE gene mutations in patients with acute myeloid leukemia. Leuk. Res. 1999, 23, 597–598. [CrossRef]
22. Gunel-Ozcan, A.; Alyilmaz-Bekmez, S.; Guler, E.N.; Guc, D. HFE H63D mutation frequency shows an increase in Turkish women with breast cancer. BMC Cancer 2006, 6, 37. [CrossRef] [PubMed]
23. Kondrashova, T.V.; Neriishi, K.; Ban, S.; Ivanova, T.I.; Krikunova, L.I.; Smirkova, I.A.; Konova, M.V.; Taira, S.; Tsyb, A.F. Frequency of hemochromatosis gene (HFE) mutations in Russian healthy women and patients with estrogen-dependent cancers. Biochim. Biophys. Acta 2006, 1762, 59–65. [CrossRef] [PubMed]
24. Macdonald, G.A.; Tarish, J.; Whitehall, V.J.; McCann, S.J.; Buttenshaw, R.L.; Johnson, A.G.; Young, J.; Leggett, B.A. No evidence of increased risk of colorectal cancer in individuals heterozygous for the Cys282Tyr haemochromatosis mutation. J. Gastroenterol. Hepatol. 1999, 14, 1188–1191. [CrossRef] [PubMed]
25. Martinez di Montemuros, F.; Tavazzi, D.; Salsano, E.; Piepoli, T.; Pollo, B.; Fiorelli, G.; Finocchiaro, G. High frequency of the H63D mutation of the hemochromatosis gene (HFE) in malignant gliomas. Neurology 2001, 57, 1342. [CrossRef] [PubMed]
26. Robinson, J.P.; Johnson, V.L.; Rogers, P.A.; Houlston, R.S.; Maher, E.R.; Bishop, D.T.; Thomas, H.J.; Tomlison, I.P.; Silver, A.R. Evidence for an association between compound heterozygosity for germ line mutations in the hemochromatosis (HFE) gene and increased risk of colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 1460–1463. [CrossRef] [PubMed]
27. Shaheen, N.J.; Silverman, L.M.; Keku, T.; Lawrence, L.B.; Rohifs, E.M.; Martin, C.F.; Galanko, J.; Sandler, R.S. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J. Natl. Cancer Inst. 2003, 95, 154–159. [CrossRef] [PubMed]
28. Van der A.D.L.; vander Hel, O.; Roest, M.; van der Schouw, Y.T.; van Gils, C.H.; van Noord, P.A.; Peeters, P.H.M. Heterozygosity for the Cys282Tyr mutation in the HFE gene and the risk of colorectal cancer (Netherlands). Cancer Causes Control 2003, 14, 541–545. CrossRef] [PubMed]
29. Ellervik, C.; Birgens, H.; Tybjaerg-Hansen, A.; Nordestgaard, B.G. Hemochromatosis genotypes and risk of 31 disease endpoints: Meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007, 46,1071–1080. [CrossRef] [PubMed]
30. Chen, W.; Zhao, H.; Li, T.; Yao, H. HFE gene C282Y variant is associated with colorectal cancer in Caucasians: A meta-analysis. Tumour Biol. 2013, 34, 2255–2259. [CrossRef] [PubMed]
31. Agudo, A.; Bonet, C.; Sala, N.; Munoz, X.; Aranda, N.; Fonseca-Nunes, A.; Clavel-Chapelton, F.; Boutron-Rault, M.C.; Vineis, P.; Panico, S. et al. Hemochromatosis (HFE) gene mutations and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Carcinogenesis 2013, 34, 1244–1250. [CrossRef] [PubMed]
32. Richie, J.P.; Kleinman, W.; Marina, P.; Abraham, P.; Wynder, E.L.; Muscat, J.E. Blood iron, glutathione, and micronutrient levels and the risk of oral cancer. Nutr. Cancer 2008, 60, 474–482. [CrossRef] [PubMed]
33. Patel, B.P.; Rawal, U.M.; Rawal, R.M.; Shukla, S.N.; Patel, P.S. Tobacco, antioxidant enzymes, oxidative stress, and genetic susceptibility in oral cancer. Am. J. Clin. Oncol. 2008, 31, 454–459. [CrossRef] [PubMed]
34. Novacek, G. Plummer-Vinson syndrome. Orphanet J. Rare Dis. 2006, 1, 36. [CrossRef] [PubMed]
35. Pedersen, P.; Milman, N. Genetic screening for HFE hemochromatosis in 6,020 Danish men: Penetrance of C282Y, H63D, and S65C variants. Ann. Hematol. 2009, 88, 775–784. [CrossRef] [PubMed]
36. Muscat, J.E.; Richie, J.P.; Thompson, S.; Wynder, E.L. Gender differences in smoking and risk for oral cancer. Cancer Res. 1996, 56, 5192–5197. [PubMed]
37. Franco, E.L.; Kowalski, L.P.; Oliveira, B.V.; Curado, M.P.; Pereira, R.N.; Silva, M.E.; Fava, A.S.; Torloni, H. Risk factors for oral cancer in Brazil: A case-control study. Int. J. Cancer 1989, 43, 992–1000. [CrossRef][PubMed]
38. Ausubel, F.M.; Brent, R.; Kingston, R.; Moore, D.D.; Seidman, J.G.; Smith, J.A.; Struhl, K. Current Protocols in Molecular Biology; JohnWiley and Sons: New York, NY, USA, 1989; Volume 1, pp. 211–213.
39. Elahi, A.; Bendaly, J.; Zheng, Z.; Muscat, J.E.; Richie, J.P., Jr.; Schantz, S.P.; Lazarus, P. Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk. Cancer 2003, 98, 872–880. [CrossRef][PubMed]
40. Brittenham, G. Spectrophotometric plasma iron determination from fingerpuncture specimens. Clin. Chim. Acta 1979, 91, 203–211. [CrossRef]
41. Cook, J.D. An evaluation of adsorption methods for measurement of plasma iron-binding capacity. J. Lab. Clin. Med. 1970, 76, 497–506. [PubMed]
42. Cook, J.D.; Lipschitz, D.A.; Miles, L.E.; Finch, C.A. Serum ferritin as a measure of iron stores in normal subjects. Am. J. Clin. Nutr. 1974, 27, 681–687. [PubMed]
43. Davies, L.; Welch, H.G. Epidemiology of head and neck cancer in the United States. Otolaryngol. Head Neck Surg. 2006, 135, 451–457. [CrossRef] [PubMed]
44. Altekruse, S.F., Krapcho, M., Neyman, N., Aminou, R., Waldron, W., Ruhl, J., Howlader, N., Tatalovich, Z., Cho, H., Mariotto, A., et al, Eds.; SEER Cancer Statistics Review, 1975–2007; National Cancer Institute: Bethesda, MD, USA. Available online: http://seer.cancer.gov/csr/1975_2007/ (accessed on 26 October 2015). Based on November 2009 SEER data submission, posted to the SEER web site, 2010.
45. Canto, M.T.; Devesa, S.S. Oral cavity and pharynx cancer incidence rates in the United States, 1975–1998. Oral Oncol. 2002, 38, 610–617. [CrossRef]
46. Cann, C.I.; Fried, M.P.; Rothman, K.J. Epidemiology of squamous cell cancer of the head and neck. Otolaryngol. Clin. North Am. 1985, 18, 367–388. [PubMed]
47. Hoffmann, D.; Hecht, S.S. Nicotine-derived N-nitrosamines and tobacco-related cancer: Current status and future directions. Cancer Res. 1985, 45, 935–944. [PubMed]
48. Marshall, J.R.; Boyle, P. Nutrition and oral cancer. Cancer Causes Control 1996, 7, 101–111.[CrossRef][PubMed]
49. McCoy, G.D.; Wynder, E.L. Etiological and preventive implications in alcohol carcinogenesis. Cancer Res. 1979, 39, 2844–2850. [PubMed]
50. Warnakulasuriya, S.; Sutherland, G.; Scully, C. Tobacco, oral cancer, and treatment of dependence. Oral. Oncol. 2005, 41, 244–260.[CrossRef] [PubMed]
51. Winn, D.M. Diet and nutrition in the etiology of oral cancer. Am. J. Clin. Nutr. 1995, 61, 437S–445S. [PubMed]
52. Wu, S.-H.; Lee, K.-W.; Chen, C.-H.; Lin, C.-C.; Tseng, Y.-M.; Ma, H.; Tsai, S.-M.; Tsai, L.-Y. Epistasis of oxidative stress-related enzyme genes on modulating the risks in oral cavity cancer. Clin. Chim. Acta 2010, 411, 1705–1710. [CrossRef] [PubMed]
53. Chua, A.C.; Graham, R.M.; Trinder, D.; Olynyk, J.K. The regulation of cellular iron metabolism. Crit. Rev. Clin. Lab. Sci. 2007, 44, 413–459.[CrossRef] [PubMed]
54. Ganz, T.; Nemeth, E. Regulation of iron acquisition and iron distribution in mammals. Biochim. Biophys. Acta 2006, 1763, 690–699. [CrossRef] [PubMed]
55. Ammann, R.W.; Muller, E.; Bansky, J.; Schuler, G.; Hacki, W.H. High incidence of extrahepatic carcinomas in idiopathic hemochromatosis. Scand. J. Gastroenterol. 1980, 15, 733–736. [CrossRef] [PubMed]
56. Rochette, J.; Le Gac, G.; Lassoued, K.; Ferec, C.; Robson, K.J. Factors influencing disease phenotype and penetrance in HFE haemochromatosis. Hum. Genet. 2010, 128, 233–248. [CrossRef] [PubMed]
57. Rossi, E.; Olynyk, J.K.; Jeffrey, G.P. Clinical penetrance of C282Y homozygous HFE hemochromatosis. Expert Rev. Hematol. 2008, 1, 205–216. [CrossRef] [PubMed]
58. Matthews, A.L.; Grimes, S.J.; Wiesner, G.L.; Acheson, L.S. Clinical consult: Iron overload–hereditary hemochromatosis. Prim. Care 2004, 31, 767–770, [CrossRef] [PubMed]
59. Whitfield, J.B.; Cullen, L.M.; Jazwinska, E.C.; Powell, L.W.; Heath, A.C.; Duffy, D.L.; Martin, N.G. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am. J. Hum. Genet. 2000, 66, 1246–1258. [CrossRef] [PubMed]
60. Torti, S.V.; Torti, F.M. Iron and ferritin in inflammation and cancer. Adv. Inorg. Biochem. 1994, 10, 119–137.[PubMed]
61. Weiss, G.; Goodnough, L.T. Anemia of chronic disease. N. Engl. J. Med. 2005, 352, 1011–1023. [CrossRef][PubMed]